Table 1.

Studies from 2011–2013 of Serum T levels and Mortality

Study Author	Study year	Number FU-yrs	Outcome (n)	Hazard Ratio (95% CI)	T Thresholds
Wehr [9]	2011	2078 8 yrs	CHF mortality (n=77) Other cardiac death (419)	0.38 (0.17; 0.87) * NS	FT: hi free T vs low Q4 vs Q1 Q1 <0.23nmol/L
Ohlsson [58]	2011	241 5 yrs	CV events (485) Including CV mortality	0.70 (0.56; 0.88) *	Hi TT >19.1 nmol/L
Kyriazis [6]	2011	111 3 yrs	Total mortality (48)	2.81 (1.2; 6.4)* 2.62(1.3; 5.4)*	TT<8.0nmol/L FT< 0.21nmol/L
Friedrich [26]	2011	3942	Total Mortality (330)	1.54 (1.18; 1.98)*	Low TT or IGF1 Age specific 10th percentile
Haring [8]	2011	117/1822 10 yrs	Total mortality in men with kidney dysfunction	2.52 (1.08; 5.85)*	Low TT, Age specific 10th percentile
Hyde [6]	2012	3637 5 yrs	Total mortality (605) CV mortality (207)	1.62 (1.20; 2.19) * 1.71 (1.12; 2.62)*	Low FT<2.88 ng/dL
Phillips [25]	2012	4225 15 yrs	Total mortality (236)	NS, NR	TT< 15.4 nmol/L
Haring [11]	2012	2039 men 5.5 yrs	All cause mortality (321) CV mortality (NR)	1.82 (1.30; 2.55)* 2.25 (1.30; 3.90)*	Low TT Age specific 10th percentile
Schneider [7]	2012	1892 men 10 yrs	Total mortality (204) CV mortality (58)	NS, NR	Low TT <10.4 nmol/L
Haring [27]	2013	254 5 & 10 yrs	Total mortality 42 & 104 deaths	0.74 (0.56; 0.98) yr 5 NS due to multiple tests	TT per quartile base & traject.
Gershman [28]	2013	963 12	PCa Mortality (148) Total Mortality (421)	TT 0.98 (0.58; 1.67) TT 1.07 (0.8; 1.44)	TT Q4/Q1 Also NS FT, DHT
Muraleedharan [5]	2013	581 6 yrs	Total Mortality (72)	TT 2.02 (1.2; 3.4)*	Low TT≤ 10.4 nmol/L
Yeap [12]	2013	3690 7 yrs	Total Mortality (974)	TT 0.78 (0.65; 0.94)* FT 0.72 (0.63–0.91)* DHT 0.76 (0.63; 0.91)*	Q3 lowest risk TT 12.6–15.8 nmol/L FT 183–216 pmol/L DHT 1.34–1.83 nmol/L

Abbreviations: CHF-congestive heart failure; CV-cardiovascular; DHT-dihydrotestosterone; FT-free T; NS- not significant;

NR – not reported; PCa- Prostate Cancer; TT-total T; Q-quartile

^*Significant